nach oben

Clinical and Translational Oncology

Erschienen in:

01.08.2015 | Brief Research Article

Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT)

verfasst von: S. García-Cabezas, C. Bueno, E. Rivin, J. M. Roldán, A. Palacios-Eito

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the clinical results in terms of local control, toxicity, failure pattern and toxicity of SBRT in oligometastatic patients with inoperable lung metastases.

Methods

Forty-four patients were treated (53 metastases). Dose regimen: 5 × 12 Gy (66 %), 8 × 7.5 Gy (20.8 %) and 10 × 5 Gy (13.2 %). Response was assessed using PET/CT at 6 months after SBRT.

Results

Local control at 1 and 2 years was 86.7 %. Seventy-five percent of local failures had received a BED <105 Gy. After a median follow-up of 13.3 months, 25 % experienced distant progression. Overall survival at 1 and 2 years was 86.7 and 60.4 %, and cancer-specific survival was 95.3 and 75.2 %, respectively. Grade 2 toxicity was 6.8 %. There was no grade 3–4 toxicity.

Conclusion

SBRT is effective and safe. The main failure pattern is distant progression. The selection of patients with a high probability of remaining oligometastatic is crucial for the efficiency of SBRT, both clinically and in terms of resources.

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.PubMed

Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P, Goldstraw P et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg. 1997;113(1):37–49.PubMedCrossRef

Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros L, et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 2006;45(7):808–17. doi:10.1080/02841860600908954.PubMedCrossRef

Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27(10):1579–84. doi:10.1200/JCO.2008.19.6386.PubMedCrossRef

Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol. 2010;5(7):1091–9. doi:10.1097/JTO.0b013e3181de7143.PubMed

Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008;72(2):398–403. doi:10.1016/j.ijrobp.2008.01.002.PubMedCrossRef

Zhang Y, Xiao JP, Zhang HZ, Yin WB, Hu YM. Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. Med J Beijing. 2011. doi:10.3760/cma.j.issn.0366-6999.2011.24.003.

Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2011;75(1):77–81. doi:10.1016/j.lungcan.2011.04.021.PubMedCrossRef

Baschnagel AM, Mangona VS, Robertson JM, Welsh RJ, Kestin LL, Grills IS. Lung metastases treated with image-guided stereotactic body radiation therapy. Clin Oncol. 2013;25(4):236–41. doi:10.1016/j.clon.2012.12.005.CrossRef

10.

Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, et al. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9(1):91. doi:10.1186/1748-717X-9-91.PubMedCentralPubMedCrossRef

11.

Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thoracic Dis. 2014;6(4):369–74. doi:10.3978/j.issn.2072-1439.2013.12.03.

12.

Buyyounouski MK, Balter P, Lewis B, D’Ambrosio DJ, Dilling TJ, Miller RC et al. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: report of the ASTRO Emerging Technology Committee. Radiat Oncol Biol. 2010;78(1):3–10. doi:10.1016/j.ijrobp.2010.04.010.CrossRef

13.

Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–101.PubMedCrossRef

14.

Kim H, Ahn YC, Park HC, Lim DH, Nam H. Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer. J Thorac Oncol. 2010;5(4):526–32. doi:10.1097/JTO.0b013e3181cbf622.PubMedCrossRef

15.

de Vin T, Engels B, Gevaert T, Storme G, de Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014;25(2):467–71. doi:10.1093/annonc/mdt537.PubMedCrossRef

16.

McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73(1):112–8. doi:10.1016/j.ijrobp.2008.03.062.PubMedCrossRef

17.

Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol. 2007;85(3):435–42. doi:10.1016/j.radonc.2007.10.044.PubMedCrossRef

18.

Solanki AA, Weichselbaum RR, Appelbaum D, Farrey K, Yenice KM, Chmura SJ, et al. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012;7(1):216. doi:10.1186/1748-717X-7-216.PubMedCentralPubMedCrossRef

19.

Senthi S, Haasbeek CJA, Ben JS, Senan S. Radiotherapy and oncology. Radiother Oncol. 2013;106(3):276–82. doi:10.1016/j.radonc.2013.01.004.PubMedCrossRef

20.

Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, et al. oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific micrornas. Sarkar in, ed. PLoS One. 2012;7(12):e50141. doi:10.1371/journal.pone.0050141.PubMedCentralPubMedCrossRef

Titel: Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT)
verfasst von: S. García-Cabezas
C. Bueno
E. Rivin
J. M. Roldán
A. Palacios-Eito
Publikationsdatum: 01.08.2015
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 8/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1291-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT)

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2015

Selection of a novel DNA thioaptamer against HER2 structure

Recommendations of the Spanish Brachytherapy Group of SEOR for HDR endoluminal treatments. Part 1: Oesophagus

Does vitamin D mediate inhibition of epithelial ovarian cancer by modulating cytokines?

Aberrant expression of UCA1 in gastric cancer and its clinical significance

Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells

Single fraction volumetric modulated arc radiosurgery of brain metastases

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie